Back to Article
Clinical differences between hospitalized patients with COVID-19-related pneumonia and those with influenza-related pneumonia during the omicron variant surge
Global Journal of Epidemiology and Infectious Disease
| Vol 4, Issue 1
Table 3. Treatments and outcomes by group
| COVID-19 pneumonia | Flu pneumonia | p value | ||
| Antiviral agents | ||||
| Remdesivir | 33 (71.7%) | NA | ||
| Ensitrelvir | 3 (7.8%) | NA | ||
| Molnupiravir | 8 (17.4%) | NA | ||
| Nilmatorelvir/Ritnavir | 2 (4.3%) | NA | ||
| Peramivir | NA | 2 (33.3%) | ||
| Oseltamivir | NA | 2 (33.3%) | ||
| Baloxavir marboxil | NA | 1 (16.7%) | ||
| Laninamivir | NA | 1 (16.7%) | ||
| Antibiotics | ||||
| SBT/ABPC | 31 (67.4%) | 1 (16.7%) | 0.016* | |
| TAZ/PIPC | 9 (19.6%) | 1 (16.7%) | 0.333 | |
| LVFX | 2 (4.3%) | 1 (16.7%) | 0.224 | |
| CTRX | 2 (4.3%) | 1 (16.7%) | 0.224 | |
| VCM | 1 (2.2%) | 0 | 0.715 | |
| CAZ | 1 (2.2%) | 0 | 0.715 | |
| CEZ | 1 (2.2%) | 0 | 0.715 | |
| CMZ | 1 (2.2%) | 0 | 0.715 | |
| LSFX | 1 (2.2%) | 0 | 0.715 | |
| MEPM | 0 | 1 (16.7%) | 0.005** | |
| Death | 7 (7/46=15.2%) | 0 | 0.304 |